Debio-0123 by Debiopharm International for Glioblastoma Multiforme (GBM): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Debio-0123 overview

Debio-0123 (ADC-730) is under development for the treatment of advanced solid tumors, glioblastoma multiforme, small-cell lung cancer and astrocytoma. The drug candidate is administered orally as a capsule. It acts by targeting WEE-1, a nuclear protein kinase. It was also under development for the treatment of colon and lung adenocarcinoma.

Debiopharm International overview

Debiopharm International, a subsidiary of Debiopharm Group, focuses on the development and manufacture of drugs for oncology and bacterial infections. The company offers oxaliplatin and triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.

For a complete picture of Debio-0123’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.